CRISPR Therapeutics Publishes Presentation on CTX310 Phase 1b Trial in Severe Hypertriglyceridemia

• CRISPR Therapeutics published a presentation reporting Phase 1b results for CTX310 in 10 participants with severe hypertriglyceridemia.
• A single infusion reduced triglycerides by a mean 62.8% at 30 days; ANGPTL3 fell 65.3%.
• No serious adverse events were related to CTX310; no clinically significant liver enzyme elevations occurred.
• The results support further development in late-stage trials; additional Phase 1b cohorts targeting specific lipid disorders are ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.